CURE’s skin cancer page is an extensive resource of cancer information featuring the latest skin cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on skin cancer.
December 13th 2024
Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell carcinoma.
FDA Approves Combination for Adjuvant Treatment of Melanoma Subtypes
May 1st 2018The combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted Food and Drug Administration (FDA) approval for the treatment of patients with BRAF V600E– or V600K–positive stage 3 melanoma following complete resection.
Pre-Surgical Immunotherapy Identifies Potential Benefit, Risk of Recurrence in Melanoma
April 19th 2018For patients with melanoma, administration of a PD-1 checkpoint blockade therapy in the neoadjuvant setting – meaning it was given before the main treatment – could result in improved outcomes and better insight to patient responses.
'Obesity Paradox' Offers Puzzling Survival Advantage in Men with Metastatic Melanoma
February 14th 2018While obesity is a known risk factor for more than a dozen types of cancer – and poised to take over smoking as the leading preventable cause for the disease – it may actually play a beneficial role in men with metastatic melanoma, according to a recent study published in Lancet Oncology.
Visible Melanoma Lesions Affect Patients' Physical, Emotional Quality of Life
February 8th 2018A recent study highlighted the additional psychological effects that patients with locally advanced cutaneous melanoma go through, particularly because their lesions are a visible part of their everyday life.
Body Mass Index Plays a Surprising Role in Immunotherapy's Effectiveness
February 6th 2018“Obesity has been previously investigated for its role in cancer and promoting tumor growth, at least partially by inducing a chronic inflammatory state,” the authors wrote. “However, it’s unclear how this would play out in the era of immunotherapy, where inflammation has been linked to treatment response.”
Clinical Trial Scenarios Help to Appropriately Include Patients With Brain Metastases
January 23rd 2018Clinical trials designed to evaluate the use of anti-cancer drugs for the treatment of cancer typically exclude patients whose disease has spread to the brain or CNS for a number of reasons, including the misperception that they are poor clinical trial candidates.
Tafinlar Plus Mekinist Combination Granted Priority Review for Melanoma Treatment
December 22nd 2017The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application (sNDA) for the use of Tafinlar (dabrafenib) combined with Mekinist (trametinib) as an adjuvant treatment for patients with BRAFV600E– or V600K–positive stage 3 melanoma following complete resection.